National Academies Press: OpenBook

Vaccines for the 21st Century: A Tool for Decisionmaking (2000)

Chapter: Appendix 22: Rotavirus

« Previous: Appendix 21: Rheumatoid Arthritis
Suggested Citation:"Appendix 22: Rotavirus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

APPENDIX 22
Rotavirus

DISEASE BURDEN

Epidemiology

For the purposes of the calculations in this report, the committee estimated that there are approximately 3,500,000 new infections of rotavirus in the United States each year. It was assumed that all infections occur in infants and children between birth and 4 years of age and that the incidence in infants under 1 year of age (30,000 per 100,000) is twice that in children between 1 and 4 years of age. It was assumed that rotavirus infection leads to 100 deaths per year in the United States.

Disease Scenarios

For the purposes of the calculation in this report, the committee assumed that rotavirus infection is associated with 8 days of acute diarrhea and a health utility index of .75.

COST INCURRED BY DISEASE

Table A22–1 summarizes the health care costs incurred by rotavirus infections. For the purposes of the calculations in this report, it was assumed that all infants and children with rotavirus infection incur modest costs for over-the-counter treatment (e.g., oral rehydration) or extra diapers. It was also assumed

Suggested Citation:"Appendix 22: Rotavirus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

Table A22–1 Health Care Costs Associated with Rotavirus Infection

 

% with Care

Cost per Unit

Units per Case (or per year)

Form of Treatment

Acute diarrhea

100%

$10

2.0

oral rehydration therapy

 

15%

$50

1.0

physician a

2%

$2,000

1.0

hospitalization

2%

$150

1.0

physician c

that 15% of infants and children receive medical attention. It is further assumed that a small percentage of children with rotavirus infection are hospitalized.

VACCINE DEVELOPMENT

The committee assumed that it would take 3 years until licensure of a rotavirus vaccine and that $120 million needed to be invested. During the time the committee report was in final stages of analysis and preparation, the rotavirus vaccine was approved for licensure. Table 4–1 summarizes vaccine development assumptions for all vaccines considered in this report.

VACCINE PROGRAM CONSIDERATIONS

Target Population

For the purposes of the calculations in this report, it is assumed that the target population for this vaccine is the annual birth cohort of infants. It was assumed that 90% of the target population would utilize the vaccine.

Vaccine Schedule, Efficacy, and Costs

For the purposes of the calculations in this report, it was estimated that this vaccine would cost $50 per dose and that administration costs would be $10 per dose. Default assumptions of a 3-dose series and 75% effectiveness were accepted. Table 4–1 summarizes vaccine program assumptions for all vaccines considered in this report.

RESULTS

If a vaccine program for rotavirus were implemented today and the vaccine were 100% efficacious and utilized by 100% of the target population, the annu-

Suggested Citation:"Appendix 22: Rotavirus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

alized present value of the QALYs gained would be 27,000. Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the QALYs gained would be 14,000.

If a vaccine program for rotavirus were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the health care costs saved would be $225 million. Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the health care costs saved would be $120 million.

If a vaccine program for rotavirus were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the program cost would be $720 million. Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the program cost would be $510 million.

Using committee assumptions of time and costs until licensure, the fixed cost of vaccine development has been amortized and is $3.6 million for a rotavirus vaccine.

If a vaccine program were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the cost per QALY gained is $20,000. Using committee assumptions of less-than-ideal utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the cost per QALY gained is $30,000.

See Chapters 4 and 5 for details on the methods and assumptions used by the committee for the results reported.

During the time the data for this report was being analyzed and written, a rotavirus vaccine was licensed. The calculated cost per QALY saved for a vaccine strategy for a currently licensed rotavirus vaccine (assuming 75% effectiveness and 90% utilization and all other disease burden and costs as described above) decreases slightly to approximately $26,500.

READING LIST

Glass RI, Kilgore PE, Holman RC, et al. The Epidemiology of Rotavirus Diarrhea in the United States: Surveillance and Estimates of Disease Burden. The Journal of Infectious Diseases 1996; 174:S5–11.


Matson DO. Potential Impact of Rotavirus Vaccines. URL http://rotavirus.com/potential_impact_of_rota.html (accessed August 8, 1996).


Offit PA, Clark HF. Rotavirus. In: Principles and Practice of Infectious Diseases. GL Mandell, JE Bennett, Dolin R eds. New York, NY: Churchill Livingstone, 1995, pp. 1448–1455.

Suggested Citation:"Appendix 22: Rotavirus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

Orenstein WA, Hadler S, Kuritsky JN, et al. Rotavirus Vaccines—from Licensure to Disease Reduction. The Journal of Infectious Diseases 1996; 174:8118–24.


Smith JC, Haddix AC, Teutsch SM, et al. Cost-effectiveness Analysis of a Rotavirus Immunization Program for the United States. Pediatrics 1995; 96:609–615.


Ventura SJ, Martin JA, Mathews TJ, et al. Advance Report of Final Natality Statistics, 1994. Monthly Vital Statistics Report 1996; 44.

Suggested Citation:"Appendix 22: Rotavirus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 291
Suggested Citation:"Appendix 22: Rotavirus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 292
Suggested Citation:"Appendix 22: Rotavirus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 293
Suggested Citation:"Appendix 22: Rotavirus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 294
Next: Appendix 23: Shigella »
Vaccines for the 21st Century: A Tool for Decisionmaking Get This Book
×
Buy Hardback | $72.95 Buy Ebook | $59.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Vaccines have made it possible to eradicate the scourge of smallpox, promise the same for polio, and have profoundly reduced the threat posed by other diseases such as whooping cough, measles, and meningitis.

What is next? There are many pathogens, autoimmune diseases, and cancers that may be promising targets for vaccine research and development.

This volume provides an analytic framework and quantitative model for evaluating disease conditions that can be applied by those setting priorities for vaccine development over the coming decades. The committee describes an approach for comparing potential new vaccines based on their impact on morbidity and mortality and on the costs of both health care and vaccine development. The book examines:

  • Lessons to be learned from the polio experience.
  • Scientific advances that set the stage for new vaccines.
  • Factors that affect how vaccines are used in the population.
  • Value judgments and ethical questions raised by comparison of health needs and benefits.

The committee provides a way to compare different forms of illness and set vaccine priorities without assigning a monetary value to lives. Their recommendations will be important to anyone involved in science policy and public health planning: policymakers, regulators, health care providers, vaccine manufacturers, and researchers.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!